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BACKGROUND
Treatment guidelines recommend the use of inhaled long-acting bronchodilators to 
alleviate symptoms and reduce the risk of exacerbations in patients with moderate-to-
very-severe chronic obstructive pulmonary disease (COPD) but do not specify whether 
a long-acting anticholinergic drug or a β2-agonist is the preferred agent. We investi-
gated whether the anticholinergic drug tiotropium is superior to the β2-agonist 
salmeterol in preventing exacerbations of COPD.
METHODS
In a 1-year, randomized, double-blind, double-dummy, parallel-group trial, we com-
pared the effect of treatment with 18 μg of tiotropium once daily with that of 50 μg 
of salmeterol twice daily on the incidence of moderate or severe exacerbations in 
patients with moderate-to-very-severe COPD and a history of exacerbations in the 
preceding year.
RESULTS
A total of 7376 patients were randomly assigned to and treated with tiotropium 
(3707 patients) or salmeterol (3669 patients). Tiotropium, as compared with salme-
terol, increased the time to the first exacerbation (187 days vs. 145 days), with a 17% 
reduction in risk (hazard ratio, 0.83; 95% confidence interval [CI], 0.77 to 0.90; 
P<0.001). Tiotropium also increased the time to the first severe exacerbation (haz-
ard ratio, 0.72; 95% CI, 0.61 to 0.85; P<0.001), reduced the annual number of mod-
erate or severe exacerbations (0.64 vs. 0.72; rate ratio, 0.89; 95% CI, 0.83 to 0.96; 
P = 0.002), and reduced the annual number of severe exacerbations (0.09 vs. 0.13; 
rate ratio, 0.73; 95% CI, 0.66 to 0.82; P<0.001). Overall, the incidence of serious 
adverse events and of adverse events leading to the discontinuation of treatment was 
similar in the two study groups. There were 64 deaths (1.7%) in the tiotropium group 
and 78 (2.1%) in the salmeterol group.
CONCLUSIONS
These results show that, in patients with moderate-to-very-severe COPD, tiotropium 
is more effective than salmeterol in preventing exacerbations. (Funded by Boehringer 
Ingelheim and Pfizer; ClinicalTrials.gov number, NCT00563381.)
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Chronic obstructive pulmonary dis-ease (COPD) is a leading cause of disabil-ity and death worldwide.1-3 Exacerbations 
of COPD indicate instability or worsening of the 
patient’s clinical status and progression of the dis-
ease and have been associated with the develop-
ment of complications, an increased risk of sub-
sequent exacerbations, a worsening of coexisting 
conditions, reduced health status and physical 
activity, deterioration of lung function, and an 
increased risk of death.4-7 The prevention of ex-
acerbations therefore constitutes a major goal of 
treatment.1,2
Therapy with a long-acting anticholinergic 
drug or a long-acting β2-agonist is recommended 
as first-line maintenance therapy in patients with 
moderate-to-very-severe COPD,1,2 since both of 
these drugs reduce symptoms, improve quality 
of life and lung function, and reduce the risk of 
exacerbations and hospitalizations.8-12 However, 
treatment guidelines do not specify whether a 
long-acting anticholinergic drug or a β2-agonist 
is the preferred agent.1,2
Comparative studies have indicated that tiotro-
pium is associated with a greater reduction in the 
risk of exacerbations and exacerbation-related 
hospitalizations than is salmeterol, although the 
differences were not significant.13,14 These were 
short-term studies (3 to 6 months in duration) 
and were not designed and powered to detect a 
difference in the risk of exacerbations. The Preven-
tion of Exacerbations with Tiotropium in COPD 
(POET-COPD) trial was specifically designed to 
directly compare the effects of tiotropium with 
those of salmeterol on the risk of moderate and 
severe exacerbations. A placebo group was not in-
cluded in the study, since there is substantial evi-
dence of the superiority of both tiotropium and 
salmeterol over placebo.8,12 Furthermore, a com-
parison of two active-treatment groups is in line 
with the recently growing relevance of compara-
tive-effectiveness research to guidance regarding 
treatment decisions.15,16
Me thods
Study Design and Oversight
We conducted a 1-year, randomized, double-blind, 
double-dummy, parallel-group trial at 725 centers 
in 25 countries to compare the effect of tiotropi-
um (Spiriva, Boehringer Ingelheim) with that of 
salmeterol (Serevent, GlaxoSmithKline) on moder-
ate and severe exacerbations of COPD (hereinafter 
called exacerbations) in patients with moderate-
to-very-severe COPD.17 The study was conducted 
in accordance with the provisions of the Declara-
tion of Helsinki (1996) and Good Clinical Prac-
tice guidelines. All patients provided written in-
formed consent before any study procedure was 
performed. The scientific steering committee 
(which was made up of two of the academic in-
vestigators and an external clinical researcher) 
and three employees of Boehringer Ingelheim 
developed the design and concept of the study, 
approved the statistical plan, had full access to 
the data, and interpreted the data. Onsite moni-
toring and site management were supported by a 
contract research organization (PAREXEL). The 
first draft of the manuscript and subsequent revi-
sions were written by all the authors, and all the 
authors made the decision to submit the manu-
script for publication. The statistical analysis was 
performed by an employee of the sponsor. All the 
authors had full access to the data and vouch for 
the accuracy and completeness of the data and the 
analyses, as well as the fidelity of the study to the 
protocol. (The protocol, including the statistical 
analysis plan, is available with the full text of this 
article at NEJM.org.) An independent ethics com-
mittee or institutional review board at each par-
ticipating center reviewed and approved the pro-
tocol before commencement of the study. In 
addition, an independent data and safety moni-
toring board and a mortality adjudication com-
mittee were established (Section 10 in the Sup-
plementary Appendix, available at NEJM.org).
End Points
The primary end point was the time to the first 
exacerbation of COPD. The time to the first exac-
erbation was selected as the primary end point 
because it is less likely to be affected by the intro-
duction of additional therapies or by the occur-
rence of multiple exacerbations in some pa-
tients.17 Secondary and safety end points included 
time-to-event end points, number-of-event end 
points, serious adverse events, and death (Section 
2 in the Supplementary Appendix).
An exacerbation was defined as an increase 
in or new onset of more than one symptom of 
COPD (cough, sputum, wheezing, dyspnea, or 
chest tightness), with at least one symptom 
lasting 3 days or more and leading the patient’s 
attending physician to initiate treatment with 
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systemic glucocorticoids, antibiotics, or both (cri-
terion for moderate exacerbation) or to hospital-
ize the patient (criterion for severe exacerbation). 
The determination of the end of the exacerbation 
was made on the basis of the clinical assessment 
of the investigator. Data on exacerbations (ac-
cording to the trial definition), as well as health 
care resources used to treat these exacerbations, 
were collected by means of a questionnaire that 
was administered during regular clinic visits and 
telephone contacts. When an investigator report-
ed a case of pneumonia, he or she was questioned 
as to whether the event had been confirmed by 
imaging.
Patients
Patients were eligible for inclusion in the study if 
they were at least 40 years of age and had a smok-
ing history of 10 pack-years or more, a diagnosis 
of COPD, a forced expiratory volume in 1 second 
(FEV1) after bronchodilation of ≤70% of the pre-
dicted value,18 a ratio of FEV1 to forced vital ca-
pacity (FVC) of ≤70%, and a documented history 
of at least one exacerbation leading to treatment 
with systemic glucocorticoids or antibiotics or 
hospitalization within the previous year. Spirom-
etry (FEV1 and FVC) was performed at the screen-
ing visit according to the guidelines of the Amer-
ican Thoracic Society19 and was used only for the 
assessment of the severity of COPD. Postbron-
chodilator measurements were performed 30 min-
utes after the patient inhaled 400 μg of albu terol. 
Daily peak flow was recorded over the course of 
4 months in a subgroup of patients, in conjunc-
tion with a genotyping analysis (for details, see 
Section 5 in the Supplementary Appendix); those 
data are not reported here. Full details regarding 
the exclusion criteria are provided in Section 6 in 
the Supplementary Appendix.
Procedures
After a 2-week run-in period, eligible patients 
were randomly assigned to receive, for 1 year, 
either 18 μg of tiotropium once daily, delivered 
through the HandiHaler inhalation device (Boeh-
ringer Ingelheim), plus placebo twice daily, deliv-
ered through a pressurized, metered-dose inhal-
er, or 50 μg of salmeterol twice daily, delivered 
through a pressurized, metered-dose inhaler, plus 
placebo once daily, delivered through the Handi-
Haler device (for details, see Section 7 in the 
Supplementary Appendix). All the patients were 
given instruction in the use of the HandiHaler 
and pressurized, metered-dose inhaler devices at 
visits 1 (screening) and 2 (randomization). Con-
comitant medication at baseline was defined as 
the therapy the patients were receiving at the time 
of the screening visit (visit 1). During the run-in 
period, patients who were receiving tiotropium 
were required to switch to 40 μg of ipratropium 
four times a day, and this therapy was discontin-
ued at the time of randomization. Patients who 
were receiving a long-acting β2-agonist were per-
mitted to continue the use of that medication dur-
ing the run-in period. Patients receiving fixed-
dose combinations of long-acting β2-agonists and 
inhaled glucocorticoids were instructed to switch 
to inhaled glucocorticoid monotherapy at the start 
of the treatment phase of the study. Patients were 
allowed to continue their usual medications for 
COPD, except for anticholinergic drugs and long-
acting β2-agonists, during the double-blind treat-
ment phase.
After randomization, clinic visits were sched-
uled at months 2, 4, 8, and 12, and monthly 
telephone calls were scheduled between visits. 
Patients completed a daily diary, and records were 
reviewed at each study visit to assess adherence to 
treatment and to determine whether respiratory 
symptoms met the criteria for exacerbation. Ad-
herence was not systematically assessed during 
the trial. During clinic visits and monthly tele-
phone calls, a questionnaire was administered to 
collect details regarding exacerbations of COPD. 
Adverse events leading to the discontinuation of 
treatment and serious adverse events including 
fatal events were recorded at the time of each 
clinic visit. Patients who prematurely discontin-
ued treatment were followed for vital status (i.e., 
whether they were alive and, if they had died, the 
primary cause of death) until the end of the 
planned treatment period of 360 days. Informa-
tion on vital status was considered to be complete 
for patients who attended all trial visits through 
day 360 and for those who prematurely discontin-
ued study medication but whose vital status was 
confirmed at day 360. Details of the randomiza-
tion procedures and of the procedures for con-
cealing the treatment assignments are provided 
in Section 8 in the Supplementary Appendix.
Statistical Analysis
We estimated that with a sample size of approxi-
mately 6800 patients (3400 in each treatment 
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group), the study would have 80% power to detect 
a 10% reduction with tiotropium as compared 
with salmeterol in the risk of a first exacerbation, 
with a two-sided test for the null hypothesis of a 
hazard ratio of 1 at a significance level of 0.05. A 
prespecified reestimation of the sample size (with 
the treatment assignments concealed) on the ba-
sis of the predicted event rate was performed to-
ward the end of the originally planned recruit-
ment phase and resulted in an increase of the 
sample size to a total of 7350 patients (Section 9 
in the Supplementary Appendix).
The efficacy and safety analyses included all 
the patients who underwent randomization and 
who received at least one dose of the study medi-
cation. Primary and secondary time-to-event end 
points were analyzed with the use of a Cox propor-
tional-hazards regression model including terms 
for (pooled) center and treatment; pooling was 
performed to account for study centers that re-
cruited fewer than four patients. P values were 
calculated with the use of the Wald chi-square 
statistic. Kaplan–Meier plots were constructed, 
and log-rank tests were also performed.
Number-of-event end points were compared 
between study groups with the use of Poisson re-
gression with correction for overdispersion and 
adjustment for treatment exposure. To allow for a 
clear distinction between events, individual epi-
sodes of exacerbations had to be separated by a 
gap of at least 7 days.
In keeping with the design of the study, exac-
erbations were not systematically followed up af-
ter a patient’s premature discontinuation of the 
trial medication.17 Hence, in the efficacy analysis, 
only exacerbations with onset during the time a 
patient was receiving treatment were included.7,20 
Patients who withdrew from the trial prema-
turely without having had an exacerbation were 
considered as having had no exacerbation, and in 
the time-to-event analysis, their data were cen-
sored at the time of withdrawal. In the analyses 
of secondary end points, no corrections for mul-
tiple testing have been made.
Subgroup analyses were performed for time-
to-event end points and for number-of-event end 
points with the use of the models described 
above, with additional terms for subgroups and 
for interactions of subgroups with the study treat-
ment. A post hoc subgroup analysis was per-
formed according to patients who received in-
haled glucocorticoids on a consistent basis during 
the study treatment period versus patients who 
received no inhaled glucocorticoids during the 
treatment period. Incidence rates of serious ad-
verse events were calculated as the number of 
patients with events divided by the time at risk. 
The rate of death from any cause was analyzed 
with the use of Cox regression, with treatment 
as a covariate. A Kaplan–Meier analysis was also 
performed.
R esult s
Patients
Patients were enrolled between January 2008 and 
April 2009. A total of 7384 patients underwent 
randomization, and 7376 patients (3707 in the 
tiotropium group and 3669 in the salmeterol 
group) received at least one dose of the study 
medication (Fig. 1). The baseline characteristics 
of the patients, including coexisting conditions, 
were balanced between the treatment groups 
(Table 1, and Section 11 in the Supplementary Ap-
pendix). Fewer patients in the tiotropium group 
than in the salmeterol group withdrew from the 
study prematurely: 585 patients (15.8%) vs. 648 
patients (17.7%) (hazard ratio with tiotropium, 
0.88; 95% confidence interval [CI], 0.78 to 0.98; 
P = 0.02). The Kaplan–Meier plot for the time to 
the discontinuation of treatment is shown in Fig-
ure 2A. The collection of vital status up to day 
360 was complete for 99.1% of the patients.
Exacerbations
There were 4411 individual episodes of exacerba-
tion among 2691 patients; 44% of the patients 
with an exacerbation had moderate COPD at the 
trial onset (stage II COPD, according to the clas-
sification of the Global Initiative for Chronic Ob-
structive Lung Disease [GOLD],1 which specifies 
four stages of COPD ranging from stage I, indi-
cating mild disease, to stage IV, indicating very 
severe disease). The time to the first exacerbation 
(the primary end point) was increased by 42 days 
with tiotropium as compared with salmeterol 
(187 days vs. 145 days, representing the time un-
til at least 25% of the patients [first quartile] had 
a first exacerbation), corresponding to a 17% re-
duction in risk with tiotropium (hazard ratio, 
0.83; 95% CI, 0.77 to 0.90; P<0.001). Figure 2B 
shows the Kaplan–Meier plot for the time to the 
first exacerbation. Given the fact that less than 
50% of the patients had an exacerbation (2691 of 
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7376 patients [36.5%]), it was not possible to cal-
culate the median time to the first exacerbation; 
therefore, the time to the first exacerbation in the 
first quartile of patients was calculated instead.
Tiotropium as compared with salmeterol sig-
nificantly reduced the risk of moderate exacer-
bations by 14% (hazard ratio, 0.86; 95% CI, 0.79 
to 0.93; P<0.001) and of severe exacerbations by 
28% (hazard ratio, 0.72; 95% CI, 0.61 to 0.85; 
P<0.001). The Kaplan–Meier plot for the time to a 
first severe exacerbation is shown in Figure 2C. 
In addition, tiotropium reduced the risk of exac-
erbations leading to treatment with systemic glu-
cocorticoids by 23% (hazard ratio, 0.77; 95% CI, 
0.69 to 0.85; P<0.001), exacerbations leading to 
treatment with antibiotics by 15% (hazard ratio, 
0.85; 95% CI, 0.78 to 0.92; P<0.001), and exacer-
bations leading to treatment with both systemic 
glucocorticoids and antibiotics by 24% (hazard 
ratio, 0.76; 95% CI, 0.68 to 0.86; P<0.001) (Section 
3 in the Supplementary Appendix).
The annual rate of exacerbations was 0.64 in 
the tiotropium group and 0.72 in the salmeterol 
group, corresponding to an 11% reduction in the 
rate of exacerbations with tiotropium (rate ratio, 
0.89; 95% CI, 0.83 to 0.96; P = 0.002). Treatment 
with tiotropium significantly reduced the annual 
rate of moderate exacerbations by 7% (0.54 vs. 
0.59; rate ratio, 0.93; 95% CI, 0.86 to 1.00; 
P = 0.048) and the annual rate of severe exacerba-
tions by 27% (0.09 vs. 0.13; rate ratio, 0.73; 95% 
CI, 0.66 to 0.82; P<0.001) (Section 3 in the Supple-
mentary Appendix). In addition, tiotropium re-
duced the rate of exacerbations leading to treat-
ment with systemic glucocorticoids by 18% (0.33 
vs. 0.41; rate ratio, 0.82; 95% CI, 0.76 to 0.90; 
7384 Underwent randomization
8293 Patients were assessed for eligibility
909 Withdrew during screening
or did not meet entry criteria
3711 Were assigned to receive
tiotropium
3673 Were assigned to receive
salmeterol
648 Discontinued salmeterol
292 Had adverse event
24 Had lack of efficacy
209 Withdrew consent
74 Were nonadherent
to protocol
15 Were lost to follow-up
34 Had other reason
585 Discontinued tiotropium
264 Had adverse event
32 Had lack of efficacy
192 Withdrew consent
66 Were nonadherent 
to protocol
7 Were lost to follow-up
24 Had other reason
4 Did not receive salmeterol4 Did not receive tiotropium
3122 Completed study 3021 Completed study
3707 Were included in efficacy
and safety analyses
3669 Were included in efficacy
and safety analyses
Figure 1. Screening, Randomization, and Follow-up.
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P<0.001), exacerbations leading to treatment with 
antibiotics by 10% (0.53 vs. 0.59; rate ratio, 0.90; 
95% CI, 0.84 to 0.97; P = 0.004), and exacerbations 
leading to treatment with both systemic gluco-
corticoids and antibiotics by 20% (0.23 vs. 0.28; 
rate ratio, 0.80; 95% CI, 0.73 to 0.88; P<0.001) 
(Section 3 in the Supplementary Appendix).
The effects of tiotropium as compared with 
salmeterol on the time to a first exacerbation and 
the annual rate of exacerbations per patient were 
consistent across prespecified subgroups accord-
ing to age, sex, smoking status (current vs. non-
current smoker), severity of COPD (GOLD stage), 
body-mass index, and use or no use of inhaled 
glucocorticoids at baseline (Fig. 3, and Section 4 
in the Supplementary Appendix). Patients with a 
low body-mass index or very severe COPD seemed 
to benefit most from tiotropium therapy (Fig. 3). 
However, the P values for the tests of an interac-
tion between treatment effect and subgroup were 
0.17 for the subgroup according to body-mass 
index and 0.05 for the subgroup according to 
GOLD stage. In a post hoc analysis, a similar re-
duction in the risk of an exacerbation with tiotro-
pium as compared with salmeterol was observed 
among the 2932 patients who used concomitant 
inhaled glucocorticoids during the study-treat-
ment period (hazard ratio, 0.91; 95% CI, 0.82 to 
1.02), as well as among the 4046 patients who did 
not use inhaled glucocorticoids at any time dur-
ing the study-treatment period (hazard ratio, 
0.81; 95% CI, 0.72 to 0.91). In a subgroup analysis 
of patients who were receiving inhaled glucocor-
ticoids at baseline but did not receive them during 
the study-treatment period versus patients who 
were receiving inhaled glucocorticoids at baseline 
and continued to receive them during the study-
treatment period, the annual exacerbation rate in 
the tiotropium group was 0.67 (95% CI, 0.57 to 
0.79) among the 395 patients who discontinued 
the use of inhaled glucocorticoids, as compared 
with 0.78 (95% CI, 0.73 to 0.85) among the 1452 
Table 1. Baseline Characteristics of the Patients.*
Characteristic
Tiotropium 
(N = 3707)
Salmeterol 
(N = 3669)
Male sex (%) 74.4 74.9
Age (yr) 62.9±9.0 62.8±9.0
Smoking status
Current smoker (%) 48.0 48.3
Smoking history (pack-yr) 38.8±20.0 37.8±19.2
Duration of COPD (yr)† 8.0±6.7 7.9±6.5
GOLD stage (%)‡
II 47.8 49.6
III 43.1 42.1
IV 8.9 7.9
Spirometry after bronchodilation§
FEV1 (liters) 1.41±0.47 1.41±0.45
FEV1 (% of predicted value) 49.2±13.3 49.4±13.1
FVC (liters) 2.71±0.81 2.75±0.82
Ratio of FEV1 to FVC (%) 52.5±10.8 52.4±11.2
Pulmonary medications (%)
Any 90.0 89.9
Anticholinergic drug
Tiotropium 30.5 30.3
Short-acting 29.3 29.6
β2-Agonists
Long-acting¶ 51.5 51.5
Short-acting 52.5 53.4
Glucocorticoids
Inhaled¶ 53.6 53.3
With tiotropium 18.7 18.2
With long-acting β2-agonists 43.3 43.5
Oral 2.4 2.3
Methylxanthines 23.0 21.2
* Plus–minus values are means ±SD. COPD denotes chronic obstructive pul-
monary disease, FEV1 forced expiratory volume in 1 second, and FVC forced 
vital capacity.
† Data on duration of COPD were missing for 15 patients in the tiotropium 
group and 5 in the salmeterol group.
‡ The severity of COPD was defined according to the classification of the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD), which specifies four 
stages of COPD ranging from stage I, indicating mild disease, to stage IV, indi-
cating very severe disease. There were 23 patients with GOLD stage I COPD — 
0.2% of the patients in the tiotropium group and 0.4% in the salmeterol group.
§ Pulmonary function testing was performed at the screening visit (visit 1). Data 
on FVC were missing for 1 patient in the tiotropium group.
¶ This medication was used either alone or in a fixed combination.
Figure 2 (facing page). Kaplan–Meier Curves for the 
Primary and Selected Secondary Outcomes.
Kaplan–Meier curves are shown for the probability of 
premature discontinuation of the study medication 
(Panel A), the probability of a first exacerbation of 
chronic obstructive pulmonary disease (COPD) (Panel 
B), and the probability of a first severe exacerbation of 
COPD leading to hospitalization (Panel C) in the tio-
tropium and salmeterol groups. The hazard ratios are 
based on a Cox proportional-hazards regression model 
including terms for (pooled) center and treatment. CI 
denotes confidence interval.
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patients who continued to receive them; the an-
nual exacerbation rate in the salmeterol group 
was 0.86 (95% CI, 0.74 to 0.99) among the 416 
patients who discontinued the use of inhaled 
glucocorticoids, as compared with 0.81 (95% CI, 
0.75 to 0.88) among the 1401 patients who con-
tinued to receive them.
SAFETY
A total of 545 patients (14.7%) in the tiotropium 
group and 606 (16.5%) in the salmeterol group 
reported a serious adverse event during the study-
treatment period (Table 2). The most common 
serious adverse event with a frequency of 0.5% or 
greater was an exacerbation of COPD, which oc-
curred in 270 patients (7.3%) in the tiotropium 
group and in 335 (9.1%) in the salmeterol group 
(Section 12 in the Supplementary Appendix).
A total of 180 cases of pneumonia were re-
ported, of which 158 (87.8%) were radiologically 
confirmed (70 in the tiotropium group and 88 in 
the salmeterol group). There were more patients 
with at least one radiologically confirmed episode 
of pneumonia among those who received con-
comitant medication with inhaled glucocorti-
coids for at least 1 day during the study-treatment 
period than among those who received no in-
haled glucocorticoid during the study-treatment 
period — 89 of 3330 patients (2.7%), of whom 
72 required hospitalization, as compared with 
59 of 4046 patients (1.5%), of whom 46 required 
hospitalization.
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Figure 3. Subgroup Analysis of the Primary End Point.
The number of patients who had at least one exacerbation of chronic obstructive pulmonary disease (COPD) with onset during the 
study-treatment period is shown according to subgroup. Hazard ratios were calculated with the use of Cox regression with terms for 
treatment. Horizontal lines represent 95% confidence intervals. The size of the squares is proportional to the size of the subgroup. The 
severity of COPD was defined according to the classification of the Global Initiative for Chronic Obstructive Lung Disease (GOLD), 
which specifies four stages of COPD ranging from stage I, indicating mild disease, to stage IV, indicating very severe disease. Noncur-
rent smokers included former smokers and one person who had never smoked. The body-mass index (BMI) is the weight in kilograms 
divided by the square of the height in meters.
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There were 142 deaths during the planned 
treatment period of 360 days (including deaths 
among patients who had withdrawn from the 
study prematurely and whose vital status was re-
corded at 360 days): 64 in the tiotropium group 
and 78 in the salmeterol group (hazard ratio with 
tiotropium, 0.81; 95% CI, 0.58 to 1.13). Addi-
tional information is provided in Section 13 in the 
Supplementary Appendix.
Discussion
Tiotropium, as compared with salmeterol, signifi-
cantly increased the time to the first moderate or 
severe exacerbation of COPD and significantly de-
creased the annual rate of exacerbations among 
patients with moderate-to-very-severe COPD. The 
benefit with tiotropium was seen consistently in 
all the major subgroups that were considered in 
this trial and was independent of the concomi-
tant use of inhaled glucocorticoids.
This 1-year study was designed and powered 
for the end point of moderate and severe exacer-
bations, one of the most relevant patient-related 
outcomes, with important effects on patients’ 
families, caregivers, health care providers, and 
payers.4-6 Any exacerbation that can be avoided 
would be beneficial from the perspective of both 
the patient and the health care system and consti-
tutes a major treatment goal in COPD.1,2
Previous large, long-term trials have shown that 
both salmeterol and tiotropium reduce the rate 
of exacerbations.8,12 However, to date, there has 
been insufficient evidence from direct compari-
sons of the two drugs; therefore, current guide-
lines do not favor one long-acting agent over the 
other for patients with COPD.1,2
The Kaplan–Meier analyses of the time to the 
first exacerbation show that the benefit with tio-
tropium as compared with salmeterol became 
evident as early as approximately 1 month after 
the initiation of treatment and was maintained 
over the entire 1-year study period. Thus, it ap-
pears to be unlikely that the difference in favor of 
tiotropium was due to early discontinuation of 
treatment among patients in the salmeterol group 
who did not have a response to that drug. Tiotro-
pium and salmeterol have been shown to reduce 
airflow limitation and hyperinflation but may also 
directly or indirectly have an effect on various 
aspects of lung inflammation.21,22 However, the 
relevance of these mechanisms to the observed 
differences in the end points related to exacerba-
tions remains to be determined. Whether the 
Table 2. Incidence Rates of Serious Adverse Events, According to System Organ Class.*
Serious Adverse Events Tiotropium (N = 3707) Salmeterol (N = 3669)
Rate Ratio for 
Tiotropium vs. 
Salmeterol
(95% CI)
no. (%)
rate/100  
patient-yr no. (%)
rate/100 
patient-yr
Respiratory, thoracic, and mediastinal events 300 (8.1) 8.66 366 (10.0) 10.99 0.79 (0.68–0.92)
Infections 96 (2.6) 2.69 109 (3.0) 3.15 0.85 (0.65–1.12)
Cardiac events 98 (2.6) 2.73 85 (2.3) 2.44 1.12 (0.84–1.50)
Neoplasms 51 (1.4) 1.42 43 (1.2) 1.23 1.15 (0.77–1.73)
Vascular events 37 (1.0) 1.03 25 (0.7) 0.71 1.44 (0.87–2.39)
Gastrointestinal events 32 (0.9) 0.89 32 (0.9) 0.92 0.97 (0.59–1.58)
Nervous system events 28 (0.8) 0.78 29 (0.8) 0.83 0.94 (0.56–1.58)
General events† 16 (0.4) 0.44 27 (0.7) 0.77 0.57 (0.31–1.07)
Injury, poisoning, and procedural complications 22 (0.6) 0.61 19 (0.5) 0.54 1.13 (0.61–2.08)
Musculoskeletal and connective-tissue events 10 (0.3) 0.28 22 (0.6) 0.63 0.44 (0.21–0.93)
* Listed are incidence rates per 100 patient-years and incidence rate ratios of serious adverse events that occurred from 
the beginning of the study-treatment period until 30 days after the last dose of study drug was received and that were 
reported by at least 0.5% of the patients in either study group. The adverse events are categorized according to the sys-
tem organ classes in the Medical Dictionary for Regulatory Activities.
† This category includes the diagnostic terms “death” and “sudden death.”
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observed differences might be due to differences 
in the aerosolizing systems, the particle size of 
the aerosols, or the distribution of the drug in the 
lung is also unknown.
The annual exacerbation rates in this study 
were lower than those in large trials involving 
patients with COPD, such as the Trial of In-
haled Steroids and Long-acting β2 Agonists 
(TRISTAN)23 and the Towards a Revolution in 
COPD Health trial (TORCH; ClinicalTrials.gov 
number, NCT00268216),8 were similar to those in 
the Understanding Potential Long-Term Impacts 
on Function with Tiotropium trial (UPLIFT, 
NCT00144339),12 and were higher than those in 
a recent 1-year study comparing the efficacy of 
two long-acting β2-agonists.24 This variability 
may reflect differences in inclusion criteria and 
in the concomitant medications, such as inhaled 
glucocorticoids, that patients were allowed to re-
ceive. In our trial, consistent with current guide-
line recommendations, concomitant therapy with 
inhaled glucocorticoids was allowed but was not 
mandatory, because the patient population in-
cluded a substantial proportion of patients with 
moderate COPD (GOLD stage II). Approximately 
40% of the patients received concomitant thera-
py with inhaled glucocorticoids on a consistent 
basis during the study-treatment period. In a post 
hoc analysis, treatment with tiotropium decreased 
the risk of exacerbations more than did treatment 
with salmeterol both in patients who were receiv-
ing inhaled glucocorticoids and in those who 
were not receiving them, suggesting that the ben-
efit of tiotropium was independent of the use of 
inhaled glucocorticoids.
In addition, the rate of exacerbations among 
patients in the tiotropium group who were re-
ceiving inhaled glucocorticoids at baseline but did 
not continue receiving them during the study-
treatment period was not higher than the rate 
among those who were receiving inhaled gluco-
corticoids at baseline and continued to receive 
them during the study-treatment period. This find-
ing is consistent with the results of the COPD 
and Seretide: a Multi-Center Intervention and 
Characterization (COSMIC) study, which showed 
that withdrawal of fluticasone for 1 year after a 
3-month run-in period with a fixed combination 
of fluticasone and salmeterol was not associated 
with an increase in moderate or severe exacer-
bations.25
Differences between study groups in the pro-
portion of patients discontinuing the study treat-
ment have been seen in other studies involving 
patients with COPD and are most often attrib-
uted to relative differences in the efficacy, safety, 
or both of the agents used in the study.7,12,26,27 
Similarly, we observed a significantly higher rate 
of premature discontinuation of treatment in the 
salmeterol group than in the tiotropium group. 
However, as compared with the between-group 
differences that have been seen in placebo-con-
trolled studies, the absolute difference was quite 
small (1.9 percentage points).
Both tiotropium and salmeterol have safety 
profiles that have been well described in the 
literature.28-31 Overall, the incidence of serious 
adverse events, adverse events leading to treat-
ment discontinuation, and fatal events were simi-
lar across treatments.
In summary, among patients with moderate-
to-very-severe COPD and a history of exacerba-
tion, tiotropium was more effective than salme-
terol in all the exacerbation end points that were 
assessed and across all major subgroups. The 
results of this large trial provide data on which 
to base the choice of long-acting bronchodilator 
therapy for maintenance treatment of COPD.
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